1. Home
  2. ARGX
Logo argenx SE

ARGX

argenx SE

as 05-30-2025 4:00pm EST

$
-
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Founded: 2008 Country:
Netherlands
Netherlands
Employees: N/A City: N/A
Market Cap: 35.3B IPO Year: 2017
Target Price: $698.22 AVG Volume (30 days): 493.8K
Analyst Decision: Strong Buy Number of Analysts: 20
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 15.94 EPS Growth: N/A
52 Week Low/High: $359.37 - $678.21 Next Earning Date: 05-08-2025
Revenue: $2,643,062,000 Revenue Growth: 82.13%
Revenue Growth (this year): 61.64% Revenue Growth (next year): 32.00%

ARGX Daily Stock ML Predictions

Share on Social Networks: